Ocular Therapeutix (OCUL) Net Cash Flow (2013 - 2026)

Ocular Therapeutix's Net Cash Flow history runs 14 years deep, the most recent figure standing at -$70.4 million for Q1 2026.

• On a quarterly basis, Net Cash Flow fell 65.86% year-over-year to -$70.4 million in Q1 2026; TTM through Mar 2026 was $317.0 million, a 337.72% increase from a year earlier, with the FY2025 full-year figure at $345.0 million, up 75.87% from the prior year.
• Net Cash Flow retreated to -$70.4 million in Q1 2026 per OCUL's latest filing, from $392.3 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $392.3 million in Q4 2025 and bottomed at -$70.4 million in Q1 2026.
• The 5-year median for Net Cash Flow is -$18.6 million (2022), against an average of $29.6 million.
• Biggest YoY gain for Net Cash Flow was 1333.48% in 2024; the steepest drop was 173.89% in 2024.
• Year by year, Net Cash Flow stood at -$18.6 million in 2022, then soared by 557.14% to $85.3 million in 2023, then slumped by 141.19% to -$35.1 million in 2024, then surged by 1217.06% to $392.3 million in 2025, then plunged by 117.94% to -$70.4 million in 2026.
• Per Business Quant, the three latest OCUL Net Cash Flow figures stand at -$70.4 million (Q1 2026), $392.3 million (Q4 2025), and -$46.4 million (Q3 2025).